Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients
NCT03925090
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG:
Cisplatin+Toripalimab
DRUG:
Cisplatin+placebo
Sponsor
Sun Yat-sen University